JP2013516469A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516469A5
JP2013516469A5 JP2012548078A JP2012548078A JP2013516469A5 JP 2013516469 A5 JP2013516469 A5 JP 2013516469A5 JP 2012548078 A JP2012548078 A JP 2012548078A JP 2012548078 A JP2012548078 A JP 2012548078A JP 2013516469 A5 JP2013516469 A5 JP 2013516469A5
Authority
JP
Japan
Prior art keywords
composition
human
antigen
immune response
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012548078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020159 external-priority patent/WO2011084967A2/en
Publication of JP2013516469A publication Critical patent/JP2013516469A/ja
Publication of JP2013516469A5 publication Critical patent/JP2013516469A5/ja
Pending legal-status Critical Current

Links

JP2012548078A 2010-01-06 2011-01-05 高齢者に保護免疫を提供するための方法及び組成物 Pending JP2013516469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29259310P 2010-01-06 2010-01-06
US61/292,593 2010-01-06
PCT/US2011/020159 WO2011084967A2 (en) 2010-01-06 2011-01-05 Methods and compositions for providing protective immunity in the elderly

Publications (2)

Publication Number Publication Date
JP2013516469A JP2013516469A (ja) 2013-05-13
JP2013516469A5 true JP2013516469A5 (https=) 2014-02-20

Family

ID=44306116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548078A Pending JP2013516469A (ja) 2010-01-06 2011-01-05 高齢者に保護免疫を提供するための方法及び組成物

Country Status (11)

Country Link
US (1) US20130095130A1 (https=)
EP (1) EP2521563B1 (https=)
JP (1) JP2013516469A (https=)
KR (1) KR20120129893A (https=)
CN (1) CN102740872A (https=)
AU (1) AU2011203740B2 (https=)
CA (1) CA2786306A1 (https=)
MX (1) MX2012007916A (https=)
SG (1) SG182305A1 (https=)
WO (1) WO2011084967A2 (https=)
ZA (1) ZA201205273B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640485A (en) 2005-01-19 2006-12-01 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2005325715B2 (en) * 2004-12-16 2011-10-06 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
NZ556004A (en) * 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
WO2006083792A2 (en) * 2005-01-31 2006-08-10 Vaxinnate Corporation Novel polypeptide ligands for toll-like receptor 2 (tlr2)
PT1861120T (pt) * 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
CN102046198A (zh) * 2008-04-25 2011-05-04 系统生物学研究所 鞭毛蛋白多肽疫苗

Similar Documents

Publication Publication Date Title
JP7523897B2 (ja) 呼吸器合胞体ウイルス(rsv)ワクチン
Al-Halifa et al. Nanoparticle-based vaccines against respiratory viruses
Sulczewski et al. Nanoparticle vaccines against viral infections
Zaman et al. Strategies for intranasal delivery of vaccines
Tao et al. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection
Jabbal-Gill Nasal vaccine innovation
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
JP2011250797A5 (https=)
JP2017538672A5 (https=)
JP2013530158A5 (https=)
JP2013518052A5 (https=)
TW201427724A (zh) 經鼻流感疫苗組成物
Watkins et al. A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles
US10874737B2 (en) Influenza nanovaccine
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
Hashemzadeh et al. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus
Cossette et al. Intranasal subunit vaccination strategies employing nanomaterials and biomaterials
JP2010506926A5 (https=)
JP2020504179A (ja) 汎用インフルエンザワクチン組成物
JP2013516469A5 (https=)
Zhao et al. Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses
Nesovic et al. Delivery of gold nanoparticle-conjugated M2e influenza vaccine in mice using coated microneedles
Zhang et al. Cationic nanoparticle-stabilized vaccine delivery system for the H9N2 vaccine to promote immune response in chickens
Stephens et al. Nanoparticle vaccines against respiratory syncytial virus
Nie et al. Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice